Sign In

CPG Infobase: Clinical Practice Guidelines

0 comment(s)

Record Id:
14309
Title:
The prognostic value of the DNMT3A biomarker in cytogenetically normal patients with acute myeloid leukemia
Fulltext:
View PDF
Author
Leber B, Ismaila N, Kamel-Reid S, Rutherford M
Publication/Review date:
2013-Nov 
Producers:
Cancer Care Ontario's Program in Evidence-based Care

Bibliographic Source

Place of Publication:
Toronto
Publisher(s):
Cancer Care Ontario's Program in Evidence-based Care
Date Accessed:
2014-01-20
Pages/Size:
19  Page(s)
References:
23
Notes:
Cancer Care Ontario Recommendation Report MOAC-1

Subject Information

Specialties:
Medical oncology, Medical genetics,
Conditions:
Leukemia;
Domains:
Diagnosis
Target Populations:
General
Target Gender:
Unknown
MeSH:
Biological Markers; DNA Mutational Analysis; Leukemia, Myelocytic, Acute; Genetic testing; Survival Analysis; Prognosis;

Copyright:

The copyright of this guideline and its companion documents belongs to: Cancer Care Ontario

Disclaimer:
All content is provided for information and education and not as a substitute for the advice of a physician. Joule assumes no responsibility or liability arising from any error or omission or from the use of any information contained herein.

Discuss this CPG

Share your ideas and expertise on this topic.

​​​